BI-3406 manufacturers
- BI-3406
-
- $67.00
-
2026-05-26
- CAS:2230836-55-0
- Purity: 99.60%
- Supply Ability: 10g
- BI-3406
-
- $67.00
-
2026-05-26
- CAS:2230836-55-0
- Purity: 99.60%
- Supply Ability: 10g
|
| | BI-3406 Basic information |
| Product Name: | BI-3406 | | Synonyms: | BI-3406;SOS1-IN-2;N-((R)-1-(3-Amino-5-(trifluoromethyl)phenyl)ethyl)-7-methoxy-2-methyl-6-(((S)-tetrahydrofuran-3-yl)oxy)quinazolin-4-amine;4-Quinazolinamine, N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7-methoxy-2-methyl-6-[[(3S)-tetrahydro-3-furanyl]oxy]-;N-[(1R)-1-[3-Amino-5-(trifluoromethyl)phenyl]ethyl]-7-methoxy-2-methyl-6-[(3S)-oxolan-3-yl]oxyquinazolin-4-amine;N-[(1R)-1-[3-Amino-5-;KRAS,interaction,anticancer,Inhibitor,BI3406,BI 3406,inhibit,Son,Sevenless,GTP-loaded,BI-3406,Ras,p38 MAPK,orally,SOS1;N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7-methoxy-2-methyl-6-[(3S)-tetrahydrofuran-3-yl]oxy-quinazolin-4-amine | | CAS: | 2230836-55-0 | | MF: | C23H25F3N4O3 | | MW: | 462.46 | | EINECS: | | | Product Categories: | APIs;API | | Mol File: | 2230836-55-0.mol |  |
| | BI-3406 Chemical Properties |
| Boiling point | 534.5±50.0 °C(Predicted) | | density | 1.347±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:100.0(Max Conc. mg/mL);216.23(Max Conc. mM)
Ethanol:100.0(Max Conc. mg/mL);216.23(Max Conc. mM) | | form | A solid | | pka | 6.58±0.70(Predicted) | | color | White to off-white | | InChIKey | XVFDNRYZXDHTHT-PXAZEXFGSA-N | | SMILES | N1=C2C(C=C(O[C@H]3CCOC3)C(OC)=C2)=C(N[C@@H](C2=CC(C(F)(F)F)=CC(N)=C2)C)N=C1C |
| | BI-3406 Usage And Synthesis |
| Uses | BI-3406 (compound I-6) is an orally active, highly potent and selective inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1) with an IC50 of 6 nM. BI-3406 potently reduces the formation of GTP-loaded KRAS, and inhibits MAPK pathway signaling. BI-3406 has anticancer activity[1][2]. | | IC 50 | KRAS-SOS1: 6 nM (IC50) | | References | [1] Michael Gmachl, et al. Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors. WO2018115380A1.
[2] Marco H Hofmann, et al. Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors. December 2019. |
| | BI-3406 Preparation Products And Raw materials |
|